Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Leading Digital Health Company Poised for Dynamic Growth as PaceMate™’s Kevin Campbell Transitions to Become biocynetic™’s Chief Innovation Officer and Rod Williams Joins as New PaceMate™ President and CEO

May 7, 2019

BRADENTON, Fla.--(BUSINESS WIRE)--May 7, 2019--PaceMate™ and its parent company biocynetic™ are excited to announce two strategic leadership shifts as Rod Williams moves from Independent Director of the board of biocynetic™ to become PaceMate™’s new President and CEO and as Dr. Kevin Campbell continues on the PaceMate™ board of directors and joins the executive team of biocynetic™ as CIO.

Since biocynetic™ and its premier brand PaceMate™ launched a unique, cloud-based, health data management platform and software, both Campbell and Williams have contributed a wealth of experience in the medical industry toward the company’s success within the digital health space.

Rod Williams Is New PaceMate™ President and CEO

Rod Williams brings more than twenty years of medical technology and customer relationship management experience to his new role with PaceMate™. His past senior executive positions at St. Jude Medical, GE Healthcare, Johnson & Johnson, and Bausch & Lomb, and his capabilities in product portfolio development and growth cycle leadership have prepared him well to move PaceMate™ forward efficiently as a digital health leader. “My breadth of executive leadership across different sectors has allowed me to learn exactly how other industries solve similar problems,” Williams said. “Bringing that particular expertise to PaceMate™ will allow us as a company to differentiate from our competitors.”

Prior to joining PaceMate™ as President and CEO, Williams served as the Corporate Vice President of Portfolio and Services with Align Technology—manufacturer of Invisalign®, as Entrepreneur-in-Residence with private equity investment firm PTV Healthcare Capital, and as President and CEO of Heart Rhythm Society Consulting Services. “My work in the heart rhythm industry has given me unique insights into problems that clinics and patients experience today as well as emerging trends and the increasing need to reduce costs while improving patient care,” he explained. “The industry overall has operated in the past much like an analog model, but the digital technology is changing, allowing patients to take full advantage of implanted smart devices. PaceMate™ is at the forefront of this development—pioneering unique proprietary technologies and leveraging the clinical expertise necessary to lead that change.”

Williams believes the future is bright for PaceMate™. “We are uniquely positioned, with biocynetic™ as our parent company, to enable data to be analyzed, making it more actionable and useful in developing more efficient services to improve customer care. PaceMate™ is poised to bring advanced features to existing products, using feedback from our customers to improve the user experience and better serve their needs.”

Kevin Campbell Takes on Greater Leadership as biocynetic™ CIO

In a coordinate strategic move to connect the premier health data platform with patient-centered care, the board of biocynetic™ has also announced Dr. Kevin Campbell’s new role as Chief Innovation Officer.

Campbell, an internationally recognized cardiologist and electrophysiologist who specializes in the diagnosis and treatment of heart rhythm disorders, joined biocynetic™ in 2017 during his service as PaceMate™’s first CEO and President. His history as medical advisor for multiple medical device vendors and as an insightful pioneer in digital health development has enabled him to propel the PaceMate™ brand forward significantly in the last eighteen months.

Dr. Campbell reviewed his role in PaceMate™’s dynamic history as a recent startup: “My experience with PaceMate™ has allowed me to see firsthand the power and potential of biocynetic™ to commercialize a portfolio of data insights and digital services which are truly unique while advancing the future of medicine in the cardiovascular space.”

Now, as biocynetic™ comes out of the shadows and establishes itself further as a pioneer in digital healthcare analytics, Campbell hopes to use his experience as physician, medical advisor, and digital thought leader to maintain close connection to PaceMate™ while expanding the parent company’s reach and commercial impact and creating strong working relationships with prominent cardiovascular researchers worldwide. “My new role encompasses strategy, development of software, understanding our data, and knowing how data can service a variety of applications and stakeholders, including patients,” Campbell explained. “My work is to bridge the gap between PaceMate™’s clinically relevant software program that is helping patients every day and the big data capabilities of biocynetic™—using collected data in predictive analytics to anticipate outbreaks, disease, and device failures.”

The board of biocynetic™ believes these changes in leadership will strengthen the PaceMate™ brand and enable biocynetic™ to focus on fully understanding the database it is creating and on development of a more intuitive user interface. “We have tremendous opportunity to leverage machine learning and neural networks in order to recognize patterns that physicians may not see during a routine clinic visit,” Campbell explained. “These are the kinds of industry advances biocynetic™ is passionate and excited about in 2019.”

About biocynetic™

biocynetic™ software receives, monitors, catalogs, and shares clinically actionable data from disparate sources. Researchers, doctors, and patients can access this data in real time through one integrated platform, reducing cost of care and improving patient outcomes. Connected big data improves workflow and increases revenue while producing real-world clinical evidence for better decision-making.

About PaceMate™

PaceMate™, powered by biocynetic™, is a complete, fully automated, vendor-neutral software + expert-service solution, filtering data into clinically actionable information and providing customized alert triage, as well as automated coding and claim prep. For more information about this 24/7/365 remote monitoring solution, visit PaceMate.com or call 1-844-4VIPMED.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005147/en/

CONTACT: Rod Williams, PaceMate™ CEO





SOURCE: PaceMate™

Copyright Business Wire 2019.

PUB: 05/07/2019 08:00 AM/DISC: 05/07/2019 08:01 AM